Related Experiment Video

Updated: Jun 3, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients

Craig W Spellman1

  • 1Center for Diabetes and Metabolic Disorders, Texas Tech University Health Science Center, Midland-Odessa, TX 79763-4206, USA. craig.spellman@ttuhsc.edu

The Journal of the American Osteopathic Association
|March 11, 2011
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) agonists offer a novel approach to managing type 2 diabetes by addressing multiple pathophysiologic defects. These agents improve glycemic control with a low risk of hypoglycemia and promote weight loss.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) pathophysiology involves complex, multifactorial defects beyond insulin resistance and beta-cell dysfunction.
  • The "ominous octet" model highlights the intricate nature of T2DM progression, complicating traditional therapeutic approaches.
  • Achieving and sustaining glycemic targets in T2DM remains a significant clinical challenge.

Observation:

  • Glucagon-like peptide-1 (GLP-1) agonists represent a significant advancement in T2DM treatment options.
  • These agents enhance insulin secretion and reduce glucagon secretion in a glucose-dependent manner.
  • GLP-1 agonists also increase satiety, leading to decreased food intake and potential weight loss.

Findings:

  • The glucose-dependent mechanism of GLP-1 agonists minimizes the risk of hypoglycemia.
  • GLP-1 agonists demonstrate beneficial effects on beta-cell function.
  • They are associated with significant weight reduction in patients with T2DM.

Implications:

  • GLP-1 agonists can be used as monotherapy for patients intolerant to metformin or in combination with other T2DM agents like metformin, thiazolidinediones, and sulfonylureas.
  • Concomitant use with dipeptidyl-peptidase-4 inhibitors is not recommended due to overlapping mechanisms of action.
  • Current FDA guidelines do not permit the concurrent use of GLP-1 agonists with insulin.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...